Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses final overall survival results from the phase 3 IMpassion130 trial in triple-negative breast cancer.
Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses final overall survival (OS) results from the phase 3 IMpassion130 trial in triple-negative breast cancer (TNBC).
The pivotal phase 3 IMpassion130 trial evaluated atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) versus placebo plus nab-paclitaxel in patients with previously untreated, locally advanced or metastatic TNBC, Iwata says.
On March 8, 2019, the FDA granted an accelerated approval to this regimen for the treatment of adult patients with metastatic TNBC whose tumors express PD-L1. This regimen also received regulatory approval in Japan, as well as in Europe, Iwata adds.
Final OS results, which were presented during the 2020 ESMO Virtual Congress, demonstrated that, in the in the intention-to-treat (ITT) population, the median OS was 21.0 months with atezolizumab plus nab-paclitaxel versus 18.7 with nab-paclitaxel alone. In the PD-L1–positive group, the median OS was 25.4 months with the combination versus 17.9 months with nab-paclitaxel alone.
Although the difference in OS between the 2 arms was not statistically significant in the ITT population, clinically meaningful OS benefit was observed in PD-L1–positive patients, Iwata concludes.